Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
10/2009
10/27/2009US7608582 Channel protein modified with a pH-responsive or light-responsive compound, coupling group C in combination with either a chargeable group or with a photocleavable chargeable group
10/27/2009US7608580 Osteogenic protein such as Bone Morphogenic Protein, hyaluronic acid derivatives and porogen or sodium bicarbonate; bone repair, or tendon, cartilage repair; allows for closed fracture repair
10/27/2009US7608282 Transdermal granisetron
10/27/2009US7608281 Retinoic acid receptors (RAR); tissue engineering, cartilage formation; for treatment of cartilage degenerative disease, skeletal trauma; bone morphogenetic protein (BMP), osteogenic protein (OP)
10/27/2009US7608280 Method of producing FR901228
10/27/2009US7608279 Stable oil in water emulsion containing deactivated immunogen such as Mycoplasma or circovirus with mineral and nonionic surfactant ; induce immunology response
10/27/2009US7608253 end-capped polyethylene glycol carbamate derivatives useful as water-soluble pro-drugs; controll hydrolytic degradation of hydrogels; conjugate polymer drug for controlled release
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2584638C Medical device for generating transient bubbles
10/27/2009CA2520813C Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
10/27/2009CA2494234C Methods and dosage forms for controlled delivery of paliperidone
10/27/2009CA2473393C Semi-fluorinated alkanes and their use
10/27/2009CA2436524C Device and procedure to generate steady compound jets of immiscible liquids and micro/nanometric sized capsules
10/27/2009CA2430318C Powder formulation and method for producing the same
10/27/2009CA2420048C Constant rate fluid delivery device with selectable flow rate and titratable bolus button
10/27/2009CA2393385C Orally administrable pharmaceutical product and method of fabrication therefor
10/27/2009CA2381580C Process for manufacturing a pharmaceutical chewing gum
10/27/2009CA2378261C Powdered material spraying device
10/27/2009CA2363792C Percutaneous absorption preparation of compound having angiotensin ii antagonistic activity
10/27/2009CA2338141C Polymer complexes of glucuronoglucanes
10/27/2009CA2320900C Biphasic controlled release delivery system for high solubility pharmaceuticals and method
10/27/2009CA2300415C Composition and device for in vivo cartilage repair
10/27/2009CA2299687C Temperature-controlled ph-dependant formation of ionic polysaccharide gels
10/27/2009CA2297801C Osmotic delivery system with semipermeable plug
10/27/2009CA2163364C Self-assembling polynucleotide delivery system comprising dendrimer polycations
10/27/2009CA2162366C Conjugation-stabilized polypeptide compositions
10/25/2009CA2629979A1 Novel resveratrol compositions
10/22/2009WO2009129531A2 Bupivacaine formulation in a polyorthoester carrier
10/22/2009WO2009129527A2 Baclofen formulation in a polyorthoester carrier
10/22/2009WO2009129510A2 Sulindac formulations in a biodegradable material
10/22/2009WO2009129509A2 Methods and compositions for treating post-operative pain comprising a local anesthetic
10/22/2009WO2009129494A2 Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation
10/22/2009WO2009129491A2 Beta adrenergic receptor agonists for treatment of pain and/or inflammation
10/22/2009WO2009129476A2 An antibody bound synthetic vesicle containing active agent molecules
10/22/2009WO2009129470A2 Methods for treating herpes virus infections
10/22/2009WO2009129464A2 Method for treating acute pain with a formulated drug depot in combination with a liquid formulation
10/22/2009WO2009129460A2 Clonidine formulations in a biodegradable polymer carrier
10/22/2009WO2009129459A1 Devices that include ethylene-vinyl acetate copolymers and methods of making and using same
10/22/2009WO2009129453A2 Clonidine formulation in a polyorthoester carrier
10/22/2009WO2009129437A2 Methods and compositions for treating post-operative pain comprising clonidine
10/22/2009WO2009129433A2 Alpha adrenergic receptor agonists for treatment of degenerative disc disease
10/22/2009WO2009129432A2 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
10/22/2009WO2009129395A1 Cationic lipids and uses thereof
10/22/2009WO2009129385A1 Cationic lipids and uses thereof
10/22/2009WO2009129336A2 Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections
10/22/2009WO2009129300A2 High density compositions containing posaconazole and formulations comprising the same
10/22/2009WO2009129297A1 Semi-solid oral pharmaceutical compositions
10/22/2009WO2009129282A1 Compositions comprising weakly basic drugs and controlled-release dosage forms
10/22/2009WO2009129210A2 Compositions and methods for treating post-operative pain using clonidine and bupivacaine
10/22/2009WO2009129155A2 Dexamethasone formulations in a biodegradable material
10/22/2009WO2009129149A2 Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
10/22/2009WO2009129148A2 Methods and compositions for treating intervertebral disc herniations
10/22/2009WO2009129147A2 Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
10/22/2009WO2009129120A2 Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
10/22/2009WO2009129101A1 Liquid buffered gdf-5 formulations
10/22/2009WO2009129094A2 Compositions containing antiviral compounds and methods of using the same
10/22/2009WO2009128930A1 Effects of probiotics on humans and animals under environmental or biological changes
10/22/2009WO2009128918A1 Combination therapy using a soluble hyaluronidase and a bisphosphonate
10/22/2009WO2009128789A1 Vesicles for intracellular drug delivery
10/22/2009WO2009128692A1 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
10/22/2009WO2009128543A1 Process for producing silica-containing tablet, tablet, and composite particle for tablet
10/22/2009WO2009128489A1 Tablet containing vancomycin hydrochloride
10/22/2009WO2009128474A1 Method of producing thrombin-immobilized bioabsorbable sheet preparation
10/22/2009WO2009128433A1 Film-like composition
10/22/2009WO2009128357A1 Bioactive protein-containing nanoparticle composition and method for producing the same
10/22/2009WO2009128273A1 Iontophoresis preparation for treating breast cancer and/or mastitis
10/22/2009WO2009128075A1 Plaster with medication dispenser
10/22/2009WO2009127922A2 Pharmaceutical formulation for treating cardiovascular disease
10/22/2009WO2009127878A1 A liquid spray solution comprising buprenorphine, ethanol and an antioxidant
10/22/2009WO2009127833A1 Steroid nebuliser formulation
10/22/2009WO2009127830A1 Compositions for the treatment of lice
10/22/2009WO2009127825A1 Topical combinations comprising an antimycotic agent and an antiviral agent
10/22/2009WO2009127802A1 Rosiglitazone composition
10/22/2009WO2009127059A1 Complexes of isogranulatimide and granulatimide with a cyclodextrm, formulations and their use for the treatment of cancer
10/22/2009WO2009106960A3 Stable compositions of lamivudine, tenofovir and efavirenz
10/22/2009WO2009102172A3 Pharmaceutical formulation containing choline alfoscerate
10/22/2009WO2009102121A3 Solid lipid nanoparticles for drug delivery, a production method therefor, and an injectable preparation comprising the nanoparticles
10/22/2009WO2009100348A3 Peptides and peptide mimetics to treat pathologies associated with eye disease
10/22/2009WO2009099959A3 Tumor cell expression of neuropilin as a target for cancer therapy
10/22/2009WO2009099650A3 Treatment of bladder diseases with a tlr7 activator
10/22/2009WO2009099467A3 Cyclosporin compositions
10/22/2009WO2009087483A3 Pharmaceutical formulations
10/22/2009WO2009086400A3 Recombinant vwf formulations
10/22/2009WO2009084975A8 Composition exhibiting high osmotic antimicrobial, anti-inflammatory and regeneration activity
10/22/2009WO2009073192A3 Systems and methods for delivery of materials
10/22/2009WO2009039508A9 Preferential killing of cancer cells and activated human t cells using zno nanoparticles
10/22/2009WO2009022174A3 Non-aggregating virus formulation
10/22/2009WO2008117154A3 Stable pharmaceutical compositions, preferably tablets, of hmg-coa reductase inhibitor and process for preparation thereof
10/22/2009WO2008102248A3 An improved monolithic drug delivery system
10/22/2009WO2008097953A8 Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
10/22/2009WO2008093347A3 Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
10/22/2009WO2008020329A3 Administration of cells and cellular extracts for rejuvenation
10/22/2009US20090264856 Safety limits for closed-loop infusion pump control
10/22/2009US20090264806 Transdermal drug administration device
10/22/2009US20090264629 Stabilized protein-containing formulations
10/22/2009US20090264600 Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid
10/22/2009US20090264538 Multifunctional polymeric tissue coatings
10/22/2009US20090264537 Biodegradable block copolymeric compositions for drug delivery
10/22/2009US20090264521 Percutaneous absorption preparation
10/22/2009US20090264497 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
1 ... 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 ... 2991